VEEV Stock Analysis — AI Buy/Sell Signals & Forecast
Real-time AI-powered analysis for VEEV with price targets, technical indicators (RSI, MACD, SMA), institutional money flow, and news-based signals.
Unlock Full Pro Analysis
Real-time alerts, price targets, institutional flow & more — one-time $19.95.
VEEV · Veeva Systems Inc.
Free summary — full analysis below.
Veeva Systems Inc.
Pre-Market & After Hours is Pro Only
Upgrade to unlock this and all premium features
Oct 8, 06:23 AM
Confidence Score is Pro Only
Upgrade to unlock this and all premium features
Optimal Buy & Sell Zones is Pro Only
Upgrade to unlock this and all premium features
Strong Uptrend — Price above SMA50 & SMA200, Golden Cross
Total Conviction Scorecard is Pro Only
Upgrade to unlock this and all premium features
Optimal Buy & Sell Zones is Pro Only
Upgrade to unlock this and all premium features
$-25.86 (-8.4%) from high
Day's Range: $279.80 – $286.98
+$134.45 (+90.8%) above low
▲ Above — short-term uptrend (bullish)
▲ Above — long-term uptrend (bullish)
✓ 0.7x avg — normal activity, signals are reliable
✓ Normal — healthy trading conditions
RSI, MACD & SMA based on daily closes — update at market close. Live price shown separately.
Institutional Money Flow is Pro Only
Upgrade to unlock this and all premium features
Phantom Flow is Pro Only
Upgrade to unlock this and all premium features
Smart Money Flow Index is Pro Only
Upgrade to unlock this and all premium features
Risk Score is Pro Only
Upgrade to unlock this and all premium features
Veeva is demonstrating strong operational momentum through the successful scaling of its data automation and AI-driven clinical trial solutions. The company's expanding footprint across both emerging and established biotech firms signals robust long-term growth potential.
Latest News & Market Impact
Jim Cramer Has Reservations About One of These Software Comebacks
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
Sector Update: Healthcare Stocks Rise Premarket Tuesday
Veeva Says DQS System Has Cleaned Data for More Than 1 Million Clinical Trial Subjects
Disclaimer: This analysis is AI-generated and should not be considered financial advice. Always consult a qualified financial advisor before making investment decisions.
VEEV Stock Analysis — Frequently Asked Questions
Is VEEV a buy or sell right now?▾
Our AI engine analyzes VEEV across technicals (RSI, MACD, SMA50/200), institutional money flow (OBV, SEC 13D/13G filings), news sentiment, and price action to produce a real-time buy/sell signal with a confidence score. The recommendation updates every time the analysis runs.
What is the price target for VEEV?▾
The analysis calculates optimal entry and exit price targets for VEEV using support/resistance levels, moving-average structure, and momentum. These levels are dynamic and recompute as new market data arrives.
What do the RSI and MACD signals say about VEEV?▾
RSI measures whether VEEV is overbought or oversold; MACD shows momentum and trend shifts. A bullish MACD crossover with RSI below 70 often signals continued upside, while divergence can warn of a reversal.
Are institutions buying VEEV?▾
We track institutional positioning in VEEV through On-Balance Volume (OBV) money flow and SEC Schedule 13D/13G filings — the same disclosures activist investors and large funds must file. Rising OBV plus new 13D filings typically indicate smart-money accumulation.
What are the main risks of investing in VEEV?▾
Key risks for VEEV include valuation compression, sector rotation, earnings volatility, and macro factors such as rates and inflation. The analysis grades risk from very low to very high based on volatility, drawdown history, and beta.
How accurate is the VEEV AI analysis?▾
The VEEV analysis combines real-time market data, technical indicators, institutional flow, and news-based sentiment. It is a decision-support tool, not financial advice — always do your own research and consider your risk tolerance before investing.
Market Intelligence provides AI-powered stock & ETF analysis for informational purposes only and does not constitute financial advice.